Valuation: Berkley Renewables Inc.

Market Cap 4L 3L 3L 3L 5L 3.49Cr 5L 35.84L 13.81L 1.78Cr 13.69L 13.38L 5.74Cr P/E 2016
4.22x
P/E 2017 -1.16x
Enterprise Value 51.26L 44.69L 42.09L 38.33L 71.87L 49Cr 71.96L 5.04Cr 1.94Cr 25Cr 1.93Cr 1.88Cr 81Cr EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
Manager TitleAgeSince
Chief Executive Officer 63 20/06/2002
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 17/08/2006
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5L
-3.26%-6.69%+38.74%+7.11% 16TCr
-2.23%-3.03%+55.62%+63.17% 10TCr
-1.98%-4.82%+21.88%+15.33% 7.57TCr
-2.78%-4.15%+89.45%+66.92% 6.01TCr
-2.70%-7.33%+24.19%-8.49% 5.88TCr
-2.10%-4.30%+40.14%+2.54% 5.59TCr
-1.64%-8.00%+35.51%+25.05% 5.39TCr
-1.76%-1.48%+39.72%-12.08% 4.38TCr
-3.21%-1.81%+56.94%+10.01% 3.6TCr
Average -2.17%-3.42%+44.69%+18.84% 6.45TCr
Weighted average by Cap. -2.51%-4.01%+43.77%+21.06%

Financials

2016 2017
Net sales 10.34L 9L 8L 8L 14.5L 9.91Cr 14.52L 1.02Cr 39.2L 5.05Cr 38.84L 37.98L 16Cr 17.25L 15.04L 14.16L 12.9L 24.18L 17Cr 24.21L 1.7Cr 65.38L 8.42Cr 64.79L 63.35L 27Cr
Net income 2L 2L 1L 1L 2L 1.65Cr 2L 16.98L 7L 84.28L 6L 6L 2.72Cr -6L -5L -5L -5L -9L -6.04Cr -9L -62.01L -23.9L -3.08Cr -23.68L -23.16L -9.93Cr
Net Debt 29.17L 25.43L 23.95L 21.82L 40.9L 28Cr 40.95L 2.87Cr 1.11Cr 14Cr 1.1Cr 1.07Cr 46Cr 47.61L 41.51L 39.1L 35.61L 66.76L 46Cr 66.84L 4.68Cr 1.8Cr 23Cr 1.79Cr 1.75Cr 75Cr
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!